RECm Stock Overview
Engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €49.02 |
| 52 Week High | €52.72 |
| 52 Week Low | €43.34 |
| Beta | 0.37 |
| 11 Month Change | 1.70% |
| 3 Month Change | n/a |
| 1 Year Change | 11.92% |
| 33 Year Change | 1.87% |
| 5 Year Change | 30.06% |
| Change since IPO | 826.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| RECm | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | -0.9% |
| 1Y | 11.9% | 9.7% | 6.3% |
Return vs Industry: RECm exceeded the UK Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: RECm exceeded the UK Market which returned 7.3% over the past year.
Price Volatility
| RECm volatility | |
|---|---|
| RECm Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: RECm has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RECm's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 4,455 | Rob Koremans | www.recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary
| RECm fundamental statistics | |
|---|---|
| Market cap | €9.93b |
| Earnings (TTM) | €388.86m |
| Revenue (TTM) | €2.14b |
25.5x
P/E Ratio4.6x
P/S RatioIs RECm overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RECm income statement (TTM) | |
|---|---|
| Revenue | €2.14b |
| Cost of Revenue | €629.37m |
| Gross Profit | €1.51b |
| Other Expenses | €1.12b |
| Earnings | €388.86m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | 1.89 |
| Gross Margin | 70.57% |
| Net Profit Margin | 18.18% |
| Debt/Equity Ratio | 93.9% |
How did RECm perform over the long term?
See historical performance and comparison